Related Experiment Videos

[Protective effect of exogenous pulmonary surfactant on pulmonary function during cardiopulmonary bypass in children]

Q Xing1, S Zhang, Z Chen

  • 1Department of Cardiovascular Surgery, Children's Hospital, Shanghai Medical University, Shanghai 200032.

Zhonghua Yi Xue Za Zhi
|October 17, 2001
PubMed

Insights

Exogenous pulmonary surfactant (PS) improved respiratory function and reduced lung damage in children after heart surgery. This study shows PS is effective in preventing respiratory insufficiency post-cardiopulmonary bypass.

Area of Science:

  • Pediatric Cardiac Surgery
  • Respiratory Medicine
  • Pulmonology

Background:

  • Cardiopulmonary bypass (CPB) can lead to respiratory insufficiency in children.
  • Pulmonary hypertension and VSD are common comorbidities in pediatric cardiac surgery patients.
  • Exogenous pulmonary surfactant (PS) is a potential therapeutic agent for lung injury.

Purpose of the Study:

  • To evaluate the protective effects of exogenous pulmonary surfactant (PS) on respiratory insufficiency in pediatric patients undergoing CPB.
  • To assess the impact of PS on lung function, oxidative stress, and recovery time after cardiac surgery.

Main Methods:

  • A randomized controlled trial involving 24 children with VSD and pulmonary hypertension undergoing CPB.
  • Exogenous natural porcine PS was administered intratracheally in the PS group; saline was given to the control group.
  • Lung dynamic compliance, oxygenation index, plasma MDA levels, intubation time, and lung ultrastructure were measured.

Main Results:

  • The PS group demonstrated significantly higher dynamic lung compliance and lower oxygenation index post-CPB compared to controls.
  • Exogenous PS significantly reduced plasma MDA levels, indicating decreased oxidative stress.
  • Intubation time was markedly shorter in the PS group (8.9 hours) versus the control group (13.8 hours), with improved lung histology.

Conclusions:

  • Exogenous natural PS provides a protective effect against respiratory insufficiency following CPB in pediatric patients with VSD and pulmonary hypertension.
  • PS administration can improve lung function, reduce lung injury markers, and accelerate recovery after complex cardiac surgery.
  • This suggests PS is a valuable therapeutic option for managing post-operative respiratory complications in this vulnerable patient population.
Abstract

Related Concept Videos